174 related articles for article (PubMed ID: 19823746)
1. In vivo siRNA delivery with dendritic poly(L-lysine) for the treatment of hypercholesterolemia.
Watanabe K; Harada-Shiba M; Suzuki A; Gokuden R; Kurihara R; Sugao Y; Mori T; Katayama Y; Niidome T
Mol Biosyst; 2009 Nov; 5(11):1306-10. PubMed ID: 19823746
[TBL] [Abstract][Full Text] [Related]
2. Efficient delivery of siRNA using dendritic poly(L-lysine) for loss-of-function analysis.
Inoue Y; Kurihara R; Tsuchida A; Hasegawa M; Nagashima T; Mori T; Niidome T; Katayama Y; Okitsu O
J Control Release; 2008 Feb; 126(1):59-66. PubMed ID: 18055057
[TBL] [Abstract][Full Text] [Related]
3. Neuroprotection by biodegradable PAMAM ester (e-PAM-R)-mediated HMGB1 siRNA delivery in primary cortical cultures and in the postischemic brain.
Kim ID; Lim CM; Kim JB; Nam HY; Nam K; Kim SW; Park JS; Lee JK
J Control Release; 2010 Mar; 142(3):422-30. PubMed ID: 19944723
[TBL] [Abstract][Full Text] [Related]
4. Structural advantage of dendritic poly(L-lysine) for gene delivery into cells.
Yamagata M; Kawano T; Shiba K; Mori T; Katayama Y; Niidome T
Bioorg Med Chem; 2007 Jan; 15(1):526-32. PubMed ID: 17035030
[TBL] [Abstract][Full Text] [Related]
5. Biodistribution characteristics of amino acid dendrimers and their PEGylated derivatives after intravenous administration.
Okuda T; Kawakami S; Maeie T; Niidome T; Yamashita F; Hashida M
J Control Release; 2006 Aug; 114(1):69-77. PubMed ID: 16814896
[TBL] [Abstract][Full Text] [Related]
6. Hydrophobic cavity formed by oligopeptide for doxorubicin delivery based on dendritic poly(L-lysine).
Niidome T; Yamauchi H; Takahashi K; Naoyama K; Watanabe K; Mori T; Katayama Y
J Biomater Sci Polym Ed; 2014; 25(13):1362-73. PubMed ID: 25040893
[TBL] [Abstract][Full Text] [Related]
7. Synthesis, characterization, and gene delivery of poly-L-lysine octa(3-aminopropyl)silsesquioxane dendrimers: nanoglobular drug carriers with precisely defined molecular architectures.
Kaneshiro TL; Wang X; Lu ZR
Mol Pharm; 2007; 4(5):759-68. PubMed ID: 17705440
[TBL] [Abstract][Full Text] [Related]
8. Tripartite siRNA micelles as controlled delivery systems for primary dendritic cells.
Boudier A; Aubert-Pouëssel A; Gérardin C; Devoisselle JM; Bégu S; Louis-Plence P; Quentin J; Jorgensen C
Drug Dev Ind Pharm; 2009 Aug; 35(8):950-8. PubMed ID: 19274590
[TBL] [Abstract][Full Text] [Related]
9. Ethylendiamine core PAMAM dendrimers/siRNA complexes as in vitro silencing agents.
Perez AP; Romero EL; Morilla MJ
Int J Pharm; 2009 Oct; 380(1-2):189-200. PubMed ID: 19577619
[TBL] [Abstract][Full Text] [Related]
10. Application of biodegradable dendrigraft poly-l-lysine to a small interfering RNA delivery system.
Kodama Y; Kuramoto H; Mieda Y; Muro T; Nakagawa H; Kurosaki T; Sakaguchi M; Nakamura T; Kitahara T; Sasaki H
J Drug Target; 2017 Jan; 25(1):49-57. PubMed ID: 27125178
[TBL] [Abstract][Full Text] [Related]
11. NFkappaB decoy delivery using dendritic poly(l-lysine) for treatment of endotoxin-induced hepatitis in mice.
Sugao Y; Watanabe K; Higuchi Y; Kurihara R; Kawakami S; Hashida M; Katayama Y; Niidome T
Bioorg Med Chem; 2009 Jul; 17(14):4990-5. PubMed ID: 19539484
[TBL] [Abstract][Full Text] [Related]
12. Efficient systemic delivery of siRNA to the mouse liver by pegylated lipopolymer.
Liu J; Van S; Ma N; Yu L
Int J Pharm; 2012 May; 427(1):58-63. PubMed ID: 22100515
[TBL] [Abstract][Full Text] [Related]
13. PEGylated lysine dendrimers for tumor-selective targeting after intravenous injection in tumor-bearing mice.
Okuda T; Kawakami S; Akimoto N; Niidome T; Yamashita F; Hashida M
J Control Release; 2006 Dec; 116(3):330-6. PubMed ID: 17118476
[TBL] [Abstract][Full Text] [Related]
14. Dendritic poly(L-lysine)-b-Poly(L-lactide)-b-dendritic poly(L-lysine) amphiphilic gene delivery vectors: roles of PLL dendritic generation and enhanced transgene efficacies via termini modification.
Li Y; Zhu Y; Xia K; Sheng R; Jia L; Hou X; Xu Y; Cao A
Biomacromolecules; 2009 Aug; 10(8):2284-93. PubMed ID: 19586045
[TBL] [Abstract][Full Text] [Related]
15. An expeditious multigram-scale synthesis of lysine dendrigraft (DGL) polymers by aqueous N-carboxyanhydride polycondensation.
Collet H; Souaid E; Cottet H; Deratani A; Boiteau L; Dessalces G; Rossi JC; Commeyras A; Pascal R
Chemistry; 2010 Feb; 16(7):2309-16. PubMed ID: 20033966
[TBL] [Abstract][Full Text] [Related]
16. Potential of poly(amidoamine) dendrimers as drug carriers of camptothecin based on encapsulation studies.
Cheng Y; Li M; Xu T
Eur J Med Chem; 2008 Aug; 43(8):1791-5. PubMed ID: 18215444
[TBL] [Abstract][Full Text] [Related]
17. Impact of surface derivatization of poly-L-lysine dendrimers with anionic arylsulfonate or succinate groups on intravenous pharmacokinetics and disposition.
Kaminskas LM; Boyd BJ; Karellas P; Henderson SA; Giannis MP; Krippner GY; Porter CJ
Mol Pharm; 2007; 4(6):949-61. PubMed ID: 17953445
[TBL] [Abstract][Full Text] [Related]
18. Hepatic siRNA delivery using recombinant human apolipoprotein A-I in mice.
Lee H; Kim SI; Shin D; Yoon Y; Choi TH; Cheon GJ; Kim M
Biochem Biophys Res Commun; 2009 Jan; 378(2):192-6. PubMed ID: 19017527
[TBL] [Abstract][Full Text] [Related]
19. Cationic poly-L-lysine dendrimers: pharmacokinetics, biodistribution, and evidence for metabolism and bioresorption after intravenous administration to rats.
Boyd BJ; Kaminskas LM; Karellas P; Krippner G; Lessene R; Porter CJ
Mol Pharm; 2006; 3(5):614-27. PubMed ID: 17009860
[TBL] [Abstract][Full Text] [Related]
20. Nitroxyl radicals-modified dendritic poly(l-lysine) as a contrast agent for Overhauser-enhanced MRI.
Niidome T; Gokuden R; Watanabe K; Mori T; Naganuma T; Utsumi H; Ichikawa K; Katayama Y
J Biomater Sci Polym Ed; 2014; 25(13):1425-39. PubMed ID: 25088777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
